SLP News & Events

Simulations Plus announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence workflows across the drug development lifecycle. These programs apply AI within scientifically grounded modeling workflows and define how next-generation workflows are deployed at scale. The close collaboration between Simulations Plus and leading pharmaceutical organizations will provide direct insight into how AI will be integrated into real-world environments-informing product direction, workflow standardization, and future commercial models. The programs will utilize Simulations Plus' major software platforms, including GastroPlus, MonolixSuite, ADMET Predictor, and Thales. Participating companies will integrate the Company's internally developed AI agents directly into model-informed drug development workflows, enabling natural language interaction, automation of data processing, coordination of simulations across multiple modeling engines, and generation of interpretable outputs from complex, multi-step pipelines.

Simulations Plus announced the extension of two separate research collaborations with the U.S. FDA and the National Institute of Environmental Health Sciences, or NIEHS. The extended projects support ongoing federal research efforts focused on the development of new approach methodologies and advancing computational approaches for food and chemical safety assessments. The extended collaborations align with federal initiatives by supporting research into the application, evaluation, and refinement of computational toxicity models. The extended agreement with the FDA's Human Foods Program allows scientists to continue research involving computational models to support chemical safety assessments for food-related substances. New federal funding dedicated to food and chemical safety modernization will provide this collaboration with expanded access to curated toxicological datasets for further training, validation, and benchmarking of Simulations Plus' AI/ML models. The extended collaboration with NIEHS focuses on computational approaches relevant to environmental and exposure-related chemical safety research. NIEHS' collaboration with Simulations Plus is part of a national effort to modernize chemical safety assessment through AI-powered new approach methodologies and will continue the application of the company's software engines to help with the design, validation, and benchmarking of new experimental systems under evaluation.

Backs FY26 revenue view $79M-$82M, consensus $80.35M.

Reports Q1 revenue $18.4M, consensus $18.06M. "We met our first quarter revenue guidance and delivered strong performance in our services segment, driven primarily by significant growth in commercialization offerings and modest gains in development projects," said Shawn O'Connor, CEO of Simulations Plus. "In software, the expected decrease in clinical operations and development revenue was only partially offset by an increase in discovery solutions."